PROM1 and neoplasm: There are other studies targeting CD133+ cells in oral cancer [52], head and neck cancer [53], breast carcinoma [54], and colorectal cancer [55] with the objective to kill tumor-initiating cells; those studies show that targeting of CD133+ cells inhibits cell proliferation and tumor initiation and could reduce or eliminate established tumors.